The combination of paclitaxel and carboplatin is the standard first-line chemotherapy for ovarian cancer as recommended by the NCCN Guidelines for Epithelial Ovarian Cancer, and is conventionally given via intravenous route every three weeks. The addition of target therapy (bevacizumab) has shown to improve progression free survival but not overall survival. Several trials have also demonstrated a clinically significant survival advantage associated with intraperitoneal chemotherapy compared to intravenous chemotherapy, and the best outcomes are consistently seen for patients who have no residual disease. This study aims to compare triweekly chemotherapy with bevacizumab versus intraperitoneal chemotherapy in patients with advanced stage ovarian cancer.
Study Type
OBSERVATIONAL
Enrollment
59
Triweekly chemotherapy with bevacizumab versus intraperitoneal chemotherapy without bevacizumab
Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital
Banqiao District, New Taipei, Taiwan
Progression free survival
Time frame: the time interval from the date of surgery or neoadjuvant chemotherapy to clinically defined recurrence, disease progression, or the last follow-up
Overall survival
Time frame: the time interval from the date of surgery or neoadjuvant chemotherapy to the date of death from any cause or the last follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.